Market Overview

Obalon Announces Second Quarter 2018 Financial Results

Share:

SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its unaudited financial results as of and for the second quarter ended June 30, 2018.

Second Quarter 2018 highlights:

  • Total revenue of $2.7 million increased 103% vs Q1-18 and 39% vs Q2-17
  • US revenue of $1.5 million increased 211% vs Q1-18 and decreased 20% vs Q2-17
  • US Reorders were $1.0 million, or 64% of US sales, an increase of 221% vs Q1-18 and 61% vs Q2-17
  • Operating loss of $9.6 million decreased 20% vs $12.1 million in Q1-18 and increased 26% vs $7.6 million in Q2-17
  • Amended loan agreement providing access to additional $10.0 million
  • Filed PMA-S response for Touch dispenser
  • Filed PMA-S for Touch-compatible Navigation system

The Company reported revenue of $2.7 million for the second quarter of 2018, compared to $1.3 million for the first quarter of 2018 and $2.0 million for the second quarter of 2017. Net loss was reported at $9.8 million for the second quarter of 2018, compared to $12.1 million for the first quarter of 2018 and $7.7 million for the second quarter of 2017. Net loss per share for the second quarter of 2018 was $0.57 as compared to $0.71 for the first quarter of 2018 and $0.46 for the second quarter of 2017.

Cost of revenue was $1.7 million for the second quarter of 2018, up from $0.8 million for the first quarter of 2018 and $1.0 million for second quarter of 2017. Gross profit for the second quarter of 2018 was $1.0 million, resulting in a gross margin of 37%, compared to a gross profit of $0.6 million and gross margin of 43% for the first quarter of 2018 and a gross profit of $1.0 million and gross margin of 50% for the second quarter of 2017.

Research and Development expense for the second quarter of 2018 totaled $3.4 million, up from $2.6 million for the first quarter of 2018 and $2.8 million for the second quarter of 2017.  Selling, General and Administrative expense decreased to $7.3 million for the second quarter of 2018 as compared to $10.0 million for the first quarter of 2018 and increased from $5.9 million for the second quarter of 2017.

Operating loss for the second quarter of 2018 was $9.6 million, down from $12.1 million for the first quarter of 2018, but up from $7.6 million for the second quarter of 2017.

As of June 30, 2018, cash, cash equivalents and short-term investments were $25.2 million.

"We are pleased with the increase in revenue compared to Q1-18, especially with reorder revenues from existing customers," said Bill Plovanic, CFO of Obalon. "In Q2-18, we reduced our cash usage by $2.7 million compared to Q1-18. We believe this, along with the $25.2 million cash on hand at the end of Q2-18 and access to an additional $10.0 million of debt, furthers our ability to support the continued development of this novel and exciting non-surgical treatment for obesity."

Call Information
A conference call to discuss second quarter 2018 financial results is scheduled for today, August 2, 2018, at 8:30 AM Eastern Time (5:30 AM Pacific Time). Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 6384879.  Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event.  The conference call will also be webcast live at: https://edge.media-server.com/m6/p/jud3fsps.

An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics, Inc. website located at http://investor.obalon.com in the "News & Events" section.

About Obalon Therapeutics, Inc. 
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.

For Obalon Therapeutics, Inc.

Investor Contact: 
William Plovanic 
Chief Financial Officer 
Obalon Therapeutics, Inc. 
Office: +1 760 607 5103 
wplovanic@obalon.com

Media: 
Megan Driscoll 
EvolveMKD
Office Phone: +1 646 517 4220 
mdriscoll@evolvemkd.com

OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except shares and per share data)

  Three Months Ended June 30,   Six Months Ended June 30,
  2018   2017   2018   2017
  (Unaudited)
Revenue $ 2,732     $ 1,963     $ 4,078     $ 3,435  
Cost of revenue 1,732     990     2,501     1,813  
Gross profit 1,000     973     1,577     1,622  
Operating expenses:              
Research and development 3,352     2,760     5,991     5,160  
Selling, general and administrative 7,250     5,853     17,256     11,793  
Total operating expenses 10,602     8,613     23,247     16,953  
Loss from operations (9,602 )   (7,640 )   (21,670 )   (15,331 )
Interest expense, net (57 )   (35 )   (94 )   (89 )
Other expense (94 )   (55 )   (115 )   (55 )
       Net loss (9,753 )   (7,730 )   (21,879 )   (15,475 )
Other comprehensive income (loss)         6     (18 )
Net loss and comprehensive loss $ (9,753 )   $ (7,730 )   $ (21,873 )   $ (15,493 )
Net loss per share, basic and diluted $ (0.57 )   $ (0.46 )   $ (1.29 )   $ (0.93 )
Weighted-average common shares outstanding, basic and diluted 17,039,876     16,637,335     17,013,529     16,599,891  


OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except shares and par value data)

  June 30, 2018   December 31, 2017
Assets (Unaudited)
Current assets:      
Cash and cash equivalents $ 24,212     $ 21,108  
Short-term investments 997     23,292  
Accounts receivable, net of allowance of $433 and $239, respectively 3,049     4,223  
Inventory 1,842     1,418  
Other current assets 857     1,714  
Total current assets 30,957     51,755  
Property and equipment, net 1,514     1,346  
Total assets $ 32,471     $ 53,101  
Liabilities and Stockholders' Equity      
Current liabilities:      
Accounts payable $ 1,445     $ 1,276  
Accrued compensation 2,132     4,494  
Deferred revenue 302     510  
Other current liabilities 2,552     1,773  
Current portion of long-term loan 3,965     1,958  
Total current liabilities 10,396     10,011  
  Deferred rent 44     13  
  Long-term loan, excluding current portion 5,980     7,964  
Total long-term liabilities 6,024     7,977  
Total liabilities 16,420     17,988  
Commitments and contingencies      
Stockholders' equity:      
Common stock, $0.001 par value; 100,000,000 and 300,000,000 shares authorized as of June 30, 2018 and December 31, 2017, respectively; 17,858,704 and 17,500,604 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively 18     18  
Additional paid-in capital 149,285     146,474  
Accumulated other comprehensive gain (loss) 1     (5 )
Accumulated deficit (133,253 )   (111,374 )
Total stockholders' equity 16,051     35,113  
Total liabilities and stockholders' equity $ 32,471     $ 53,101  


OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

  Six Months Ended June 30,
  2018   2017
  (Unaudited)
Operating activities:      
Net loss $ (21,879 )   $ (15,475 )
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 276     136  
Stock-based compensation 2,603     1,079  
Loss on disposal of fixed assets 107      
(Accretion) amortization of investment (discount) premium, net (7 )   11  
Amortization of debt discount 22     20  
Change in operating assets and liabilities:      
Accounts receivable, net 1,174     (1,757 )
Accounts receivable from related party     515  
Inventory (424 )   80  
Other current assets 857     539  
Accounts payable 275     58  
Accrued compensation (2,362 )   (116 )
Accrued clinical expenses 418     91  
Deferred revenue (208 )   85  
Other current and long term liabilities 424     326  
    Net cash used in operating activities (18,724 )   (14,408 )
Investing activities:      
Purchases of short-term investments (995 )   (64,928 )
Maturities of short-term investments 23,301     12,500  
Purchase of property and equipment (657 )   (559 )
   Net cash provided by (used in) investing activities 21,649     (52,987 )
Financing activities:      
Proceeds from stock issued under employee stock purchase plan 148     210  
Proceeds from sale of common stock upon exercise of stock options 31     37  
   Net cash provided by financing activities 179     247  
   Net increase (decrease) in cash and cash equivalents 3,104     (67,148 )
Cash and cash equivalents at beginning of period 21,108     72,975  
Cash and cash equivalents at end of period $ 24,212     $ 5,827  
Supplemental cash flow information:      
Interest paid $ 307     $ 270  
Property and equipment in accounts payable $ 106     $ 96  

 

Primary Logo

View Comments and Join the Discussion!